Session Information
2008 BIO International Convention
Click here to go to the previous page
Taking It Into Their Own Hands: Working With Patient Advocacy Groups to Fund Research
Track : Emerging Company Issues
Program Code: 853
Date: Wednesday, June 18, 2008
Time: 2:00 PM to 3:30 PM  EST
Location: 31ABC
CHAIR (S):
Tim Ingersoll, Director, Communications , BIOCOM
John Wood, Executive director, Exenatide program leader , Amylin Pharmaceuticals, Inc
SPEAKER (S):
Mark Boulding, Senior Vice President and General Counsel , PTC Therapeutics, Inc
Katie Hood, MBA, CEO, The Michael J. Fox Foundation for Parkinson's Reseach
Alan Lewis, PhD, President and CEO , Novocell, Inc
Jeffrey Ostrove, PhD, President and CEO , Ceregene, Inc
John Wood, Executive director, Exenatide program leader , Amylin Pharmaceuticals, Inc
Description
"The National Institutes of Health (NIH) is a tremendous resource for a new start-up, providing funding, expertise, materials, technologies, preclinical testing and access to clinical sites that would otherwise be difficult, if not impossible, for those on a limited budget to harness. This panel, including three NIH officials, will describe the main avenues of access to the following: SBIR/STTR, NIH-developed technologies and a wide range of research resources (such as data mining tools, clinical trial networks, toxicology testing). In addition, two biotech
industry representatives will provide views from the private sector on the benefits realized from working with the NIH."

Objective1: Educate the audience on how to compete successfully for awards and provide information on the new NIH Pipeline to Partnerships.

Objective2: Discuss novel technologies created at NIH "ripe for the picking" through licensing and/or research collaborations.

Objective3: Showcase the scientific resources available to the public.


Streaming Audio with
PowerPoint Slides
(Code: 853)
  
This session is a part of: